Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931324 | 1.00 | RORC (0.59) | RORCPOLBSMN1; SMN2MAPTNPC1 | |
| SCHEMBL3931318 | 1.00 | RORC (0.59) | RORCPOLBSMN1; SMN2MAPTNPC1 | |
| SCHEMBL13902370 | 0.88 | RORC (0.54) | RORCMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL19086454 | 0.75 | ALDH1A1 (0.53) | POLBSMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL17572363 | 0.75 | ALDH1A1 (0.53) | POLBSMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL19086453 | 0.75 | ALDH1A1 (0.53) | POLBSMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL9633488 | 0.74 | CA1 (0.51) | POLBSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL9633483 | 0.74 | CA1 (0.51) | POLBSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL11804441 | 0.71 | RORC (0.67) | RORCPOLBSMN1; SMN2MAPTNPC1 | |
| SCHEMBL1015712 | 0.70 | RORC (0.57) | RORCSMN1; SMN2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | RORC 222/4885POLB 1544/4885SMN1; SMN2 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.